BioRestorative Therapies, Inc.
BRTX
$1.79
$0.0553.17%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 43.30K | 233.60K | 89.10K | 35.00K | 19.30K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 43.30K | 233.60K | 89.10K | 35.00K | 19.30K |
| Cost of Revenue | 3.30K | 18.20K | 6.50K | -- | -- |
| Gross Profit | 40.00K | 215.40K | 82.60K | 35.00K | 19.30K |
| SG&A Expenses | 1.07M | 1.18M | 1.26M | 3.09M | 2.15M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.73M | 2.52M | 2.56M | 4.14M | 3.24M |
| Operating Income | -2.69M | -2.29M | -2.47M | -4.11M | -3.22M |
| Income Before Tax | -1.64M | -1.09M | -4.03M | -2.22M | -2.30M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.64M | -1.09M | -4.03M | -2.22M | -2.30M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.64M | -1.09M | -4.03M | -2.22M | -2.30M |
| EBIT | -2.69M | -2.29M | -2.47M | -4.11M | -3.22M |
| EBITDA | -2.64M | -2.24M | -2.42M | -4.07M | -3.18M |
| EPS Basic | -0.20 | -0.13 | -0.50 | -0.33 | -0.49 |
| Normalized Basic EPS | 0.01 | -0.08 | -0.31 | -0.21 | -0.31 |
| EPS Diluted | -0.20 | -0.13 | -0.50 | -0.33 | -0.49 |
| Normalized Diluted EPS | 0.01 | -0.08 | -0.31 | -0.21 | -0.31 |
| Average Basic Shares Outstanding | 8.13M | 8.12M | 8.12M | 6.67M | 4.69M |
| Average Diluted Shares Outstanding | 8.13M | 8.12M | 8.12M | 6.67M | 4.69M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
